Practical Advice On Vital Elements In

The CDS Coalition, led by Bradley Merrill Thompson, a medical device attorney with Epstein Becker & Green in Washington, D.C., was particularly critical of the draft guidance that the industry had been waiting on for years. In comments submitted  (PDF) to the FDA, the group said the guidance would “substantially expand the scope of FDA regulation” forcing many vendors to remove low-risk products that have been on the market for decades because it “does not simply do mundane calculations that users could do themselves.” RELATED: After a 6-year wait, FDA’s clinical

...